Oxcia AB (publ) (“Oxcia”) has today published the annual report for 2022.
Oxcia's annual report is available on the website https://Oxcia.com. In the annual report, CEO Ulrika Warpman Berglund comments: "Oxcia wants to use our positive momentum for 2023 and continue to develop our projects….Oxcia's journey is very exciting and we hope to have more investors and partners on-board for 2023 and beyond."
Annual General Meeting will be held on 13 June 2023 17:00 at Life City, Solna vägen 3, Solna.
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
Briefly about Oxcia
Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two DDR drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against inflammatory and fibrosis-related diseases, such as pulmonary fibrosis and allergic asthma, and is in the preclinical phase.
More information about Oxcia is available at www.oxcia.com